Eli Lilly's diverse portfolio shows broad growth, with significant contributions from oncology and other therapeutic areas.

US-based pharmaceutical giant Eli Lilly is focusing on weight loss medications like Mounjaro (tirzepatide), which has proven ...

In a report released yesterday, Akash Tewari from Jefferies maintained a Buy rating on Eli Lilly & Co (LLY – Research Report), with a price ...

Eli Lilly started 2024 on a strong note but struggled during the second half of the year. The drugmaker dealt with several ...

DBS analyst Nico Chen has maintained their bullish stance on LLY stock, giving a Buy rating on January 21.Invest with Confidence: Follow ...

Generics businesses achieve pretty defendable margins, yet their valuations are at material discounts to most of the Big ...

With that as the backdrop, here's a closer look at three names that could be worth more than Berkshire Hathaway just five ...

One of the hottest growth areas in the healthcare landscape these days is the obesity drug market because of a class of drugs ...

Eli Lilly (NYSE: LLY) sells many products across treatment areas, from immunology to neuroscience. Eli Lilly and Company (NYSE: LLY) will announce its fourth-quarter 2024 financial results and ...

Eli Lilly and Company (NYSE: LLY) today announced that the National Medical Products Administration (NMPA) in China has approved Kisunla™ (donanemab-azbt, 350 mg/20 mL every four weeks injection ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

The nature of the beast is yes, these drugs come off patent; the demand is there and someone could produce it more cheaply’, ...